October 31, 2014: It’s Halloween at last! In the final installment of BioSpace’s spooky-themed features, we decided to go right to the top—to the C-level suite, in fact. This is our look at some of the biotech companies that said “Off with their heads!” to their executives this year...
October 30, 2014: In light of yesterday’s ouster of Sanofi CEO Christopher Viehbacher, insiders have reported that the company’s board discussed the CEO position earlier in the year with AstraZeneca CEO Pascal Soriot.
October 30, 2014: Durham, North Carolina-based Chimerix, one of the larger players in the Ebola virus therapeutics market, announced on Wednesday that it will be selling $105 million in stock as part of a $150 million shelf offering.
October 30, 2014: AstraZeneca announced today that the U.S. Food and Drug Administration has approved Xigduo XR, also known as dapagliflozin and metformin hydrochloride, for the treatment of type 2 diabetes in adults.